文献速递肿瘤 PET/CT

[⁶⁸Ga]Ga-FAP-2286 PET/CT 在胃肠道系统恶性肿瘤治疗反应评估中的作用

The role of [⁶⁸Ga]Ga-FAP-2286 PET/CT in the evaluation of treatment response in gastrointestinal system malignancies.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-30

本研究纳入50例经病理确诊的胃肠道恶性肿瘤患者,在治疗前后各行一次[⁶⁸Ga]Ga-FAP-2286 PET/CT,共100次检查,评估治疗反应并与CT RECIST标准比较。结果显示两种标准的一致性接近完美(Kappa=0.833,p<0.05),[⁶⁸Ga]Ga-FAP-2286 PET/CT评估的治疗反应可预测总生存(p=0.02),提示其可能是评估治疗反应和监测胃肠道恶性肿瘤患者的有效工具。

要点

  • [⁶⁸Ga]Ga-FAP-2286 PET PERCIST与CT RECIST标准一致性接近完美(Kappa=0.833,p<0.05)。
  • 按PERCIST标准,疾病进展者中位总生存7.6个月,疾病稳定者19.8个月,部分或完全缓解者未达中位生存。
  • [⁶⁸Ga]Ga-FAP-2286 PET/CT评估的治疗反应可预测总生存(p=0.02)。

核心结论

  • 在胃肠道系统恶性肿瘤中,血清肿瘤标志物与[⁶⁸Ga]Ga-FAP-2286 PET得出的总肿瘤体积及总病灶FAP表达值之间呈强相关。
  • [⁶⁸Ga]Ga-FAP-2286 PET/CT评估的分子缓解可预测总生存。
  • [⁶⁸Ga]Ga-FAP-2286 PET/CT似乎是评估治疗反应和监测胃肠道恶性肿瘤患者的有效工具。

研究设计与样本

  • 纳入2020年11月至2025年1月期间因治疗反应评估而接受[⁶⁸Ga]Ga-FAP-2286 PET/CT的经病理确诊的胃肠道恶性肿瘤患者。
  • 所有图像由三名经验丰富的核医学科医生评估,记录原发肿瘤和转移灶的SUVmax、总肿瘤体积和总病灶FAP表达值,并分析血清肿瘤标志物水平。
  • 分别按[⁶⁸Ga]Ga-FAP-2286 PET/CT的PERCIST标准和CT的RECIST标准评估影像学反应。
  • 采用Kaplan-Meier法分析生存结局,采用Log-Rank(Mantel-Cox)检验和Cox比例风险回归评估其与[⁶⁸Ga]Ga-FAP-2286 PET/CT治疗反应的关系,所有分析以p值<0.05为统计学显著。

主要发现

  • 共50例患者(平均年龄61.62 ± 12.95岁)在治疗前后接受100次[⁶⁸Ga]Ga-FAP-2286 PET/CT检查。
  • 纳入患者中70%为胃癌,14%为结肠癌,8%为胰腺癌,4%为阑尾癌,2%为肝细胞癌(HCC),2%为胆管细胞癌。
  • 62%的患者观察到原发/复发肿瘤病灶,24%有淋巴结转移,10%有内脏转移,76%有腹膜转移,14%有骨转移。
  • [⁶⁸Ga]Ga-FAP-2286 PET/CT测量的肿瘤体积和总病灶FAP表达值与相应血清肿瘤标志物呈强相关(delta肿瘤体积与总病灶FAP表达的曲线下面积[AUC]=0.875)。
  • [⁶⁸Ga]Ga-FAP-2286 PET PERCIST与CT RECIST标准之间一致性有统计学意义且接近完美(Kappa=0.833,p<0.05);原发肿瘤(Kappa=0.526,p<0.05)和骨转移(Kappa=0.657,p<0.05)为中等一致,淋巴结(Kappa=1.0,p<0.05)、腹膜(Kappa=0.815,p<0.05)和内脏转移(Kappa=1.0,p<0.05)为极好一致。

关键数值与推荐

  • [⁶⁸Ga]Ga-FAP-2286 PET PERCIST与CT RECIST标准的一致性Kappa=0.833(p<0.05)。
  • 原发肿瘤Kappa=0.526(p<0.05),骨转移Kappa=0.657(p<0.05),淋巴结Kappa=1.0(p<0.05),腹膜转移Kappa=0.815(p<0.05),内脏转移Kappa=1.0(p<0.05)。
  • delta肿瘤体积与总病灶FAP表达的AUC=0.875。
  • 所有分析以p值<0.05为统计学显著。

临床怎么用

  • 原文结论认为[⁶⁸Ga]Ga-FAP-2286 PET/CT似乎是评估治疗反应和监测胃肠道恶性肿瘤患者的有效工具。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to investigate the potential efficacy of [⁶⁸Ga]Ga-FAP-2286 PET/CT in evaluating treatment response in patients with gastrointestinal system malignancies. MATERIALS AND METHODS: Patients with histopathologically confirmed gastrointestinal malignancies who underwent [⁶⁸Ga]Ga-FAP-2286 PET/CT for treatment response assessment between November 2020 and January 2025 were included. All images were evaluated by three experienced nuclear medicine physicians. The maximum standardized uptake values (SUVmax), total tumor volumes, and total lesion FAP expression values of primary tumors and metastases were recorded. At the same time, serum tumor marker levels were analyzed. Imaging responses were assessed separately according to PERCIST criteria on [⁶⁸Ga]Ga-FAP-2286 PET/CT and RECIST criteria on CT. Survival outcomes were analyzed using the Kaplan-Meier method, and their association with treatment response on [⁶⁸Ga]Ga-FAP-2286 PET/CT was assessed using the Log-Rank (Mantel-Cox) test and Cox proportional hazards regression. A p-value < 0.05 was considered statistically significant in all analyses. RESULTS: A total of 100 [⁶⁸Ga]Ga-FAP-2286 PET/CT scans were performed in 50 patients (mean age: 61.62 ± 12.95), both before and after treatment. Among the included patients, 70% had gastric cancer, 14% had colon cancer, 8% had pancreatic cancer, 4% had appendiceal cancer, 2% had hepatocellular carcinoma (HCC), and 2% had cholangiocellular carcinoma. Primary/recurrent tumor lesions were observed in 62% of patients, lymph node metastases in 24%, visceral metastases in 10%, peritoneal metastases in 76%, and bone metastases in 14%. A strong correlation was found between tumor volumes and total lesion FAP expression measured by [⁶⁸Ga]Ga-FAP-2286 PET/CT and the corresponding serum tumor markers (Area Under the Curve [AUC] for delta tumor volume and total lesion FAP expression = 0.875). There was a statistically significant and near-perfect concordance between [⁶⁸Ga]Ga-FAP-2286 PET PERCIST and CT RECIST criteria (Kappa = 0.833, p < 0.05). Moderate agreement was found for primary tumors (Kappa = 0.526, p < 0.05) and bone metastases (Kappa = 0.657, p < 0.05), while excellent agreement was observed for lymph node (Kappa = 1.0, p < 0.05), peritoneal (Kappa = 0.815, p < 0.05), and visceral metastases (Kappa = 1.0, p < 0.05). According to the Kaplan-Meier analysis, treatment response assessed by [⁶⁸Ga]Ga-FAP-2286 PET/CT was predictive of overall survival (p = 0.02). Median overall survival was 7.6 months in patients with progressive disease and 19.8 months in those with stable disease, as defined by PERCIST criteria. Median survival was not reached in patients showing partial or complete response. CONCLUSION: In gastrointestinal system malignancies, a strong correlation was observed between serum tumor markers and both total tumor volumes and total lesion FAP expression values derived from [⁶⁸Ga]Ga-FAP-2286 PET imaging. Additionally, molecular response assessed by [⁶⁸Ga]Ga-FAP-2286 PET/CT was predictive of overall survival. [⁶⁸Ga]Ga-FAP-2286 PET/CT appears to be an effective tool for assessing treatment response and monitoring patients with gastrointestinal malignancies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Selcuk NA, Beydagi G, Akcay K, et al. The role of [⁶⁸Ga]Ga-FAP-2286 PET/CT in the evaluation of treatment response in gastrointestinal system malignancies. Eur J Nucl Med Mol Imaging. 2025. PMID: 41023236. doi:10.1007/s00259-025-07597-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。